Charles River Laboratories International (Charles River Laboratories International) Forward Dividend Yield % : 0.00% (As of Apr. 27, 2024)

View and export this data going back to 2000. Start your Free Trial

What is Charles River Laboratories International Forward Dividend Yield %?

As of today (2024-04-27), the Forward Annual Dividend Yield of Charles River Laboratories International is 0.00%.

As of today (2024-04-27), the Trailing Annual Dividend Yield of Charles River Laboratories International is 0.00%.

CRL's Forward Dividend Yield % is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 1.94
* Ranked among companies with meaningful Forward Dividend Yield % only.

Charles River Laboratories International's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Charles River Laboratories International's Forward Dividend Yield %

For the Diagnostics & Research subindustry, Charles River Laboratories International's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Charles River Laboratories International's Forward Dividend Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Charles River Laboratories International's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Charles River Laboratories International's Forward Dividend Yield % falls into.

Charles River Laboratories International Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Charles River Laboratories International (NYSE:CRL) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Charles River Laboratories International Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Charles River Laboratories International's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Charles River Laboratories International (Charles River Laboratories International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Charles River Laboratories International Inc (NYSE:CRL) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

CRL:Mexico RV6:Germany

Address

251 Ballardvale Street, Wilmington, MA, USA, 01887

Website

https://www.criver.com

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Executives

Victoria L Creamer	officer: EVP & Chief People Officer	164 PINE HILL ROAD, NEW FAIRFIELD CT 06812
Joseph W Laplume	officer: EVP, Corp Strategy & Develop	251 BALLARDVALE STREET, WILMINGTON MA 01887
Birgit Girshick	officer: Corporate Executive VP	251 BALLARDVALE STREET, WILMINGTON MA 01887
James C Foster	director, officer: President and CEO	251 BALLARDVALE ST, WILMINGTON MA 01887
Richard F Wallman	director	HONEYWELL, 101 COLUMBIA ROAD, MORRISTOWN NJ 07962
William D Barbo	officer: Corporate Executive VP & CCO	251 BALLARDVALE STREET, WILMINGTON MA 01887
Michael Gunnar Knell	officer: CSVP&Chief Accounting Officer	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
George Massaro	director
Shannon M Parisotto	officer: CEVP, Disc & Safety Assessment	251 BALLARDVALE ST, WILMINGTON MA 01887
Flavia Pease	officer: Corporate Executive VP	251 BALLARDVALE STREET, WILMINGTON MA 01887
David Ross Smith	officer: Corporate Executive VP & CFO	251 BALLARDVALE STREET, WILMINGTON MA 01887
Deborah Turner Kochevar	director	251 BALLARDVALE STREET, WILMINGTON MA 01887
Milne George M Jr	director
Stephen D Chubb	director	C/O MATRITECH INC, 330 NEVADA STREET, NEWTON MA 02460
George Llado	director	251 BALLARDVALE STREET, WILMINGTON MA 01887